Genotyping of a family with a novel deleteriousDPYDmutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio

Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity

(2014) S. M. Offer et al.   CANCER RESEARCH

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS

(2014) Dan Rosmarin et al.   GUT

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

(2014) Dan Rosmarin et al.   JOURNAL OF CLINICAL ONCOLOGY

DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)

(2014) Adam M. Lee et al.   JNCI-Journal of the National Cancer Institute

A DPYD Variant (Y186C) Specific to Individuals of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects: Potential for an Individualized Medicine Approach

(2014) Muhammad Wasif Saif et al.   MAYO CLINIC PROCEEDINGS

microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites

(2014) S. M. Offer et al.   MOLECULAR CANCER THERAPEUTICS

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio

(2014) Johanna Sistonen et al.   PHARMACOGENOMICS

Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity

(2013) S. M. Offer et al.   CANCER RESEARCH

A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity

(2013) S M Offer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

(2013) K E Caudle et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients

(2013) MH Kristensen et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

(2013) M C van Staveren et al.   PHARMACOGENOMICS JOURNAL

Validation of an Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantifying Uracil and 5,6-Dihydrouracil in Human Plasma

(2012) François Coudoré et al.   JOURNAL OF CHROMATOGRAPHIC SCIENCE

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

(2011) Ursula Amstutz et al.   PHARMACOGENOMICS

Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?

(2010) Joseph Ciccolini et al.   Clinical Colorectal Cancer

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

(2010) André B. P. van Kuilenburg et al.   HUMAN GENETICS

Dihydropyrimidine Dehydrogenase Deficiency Caused by a Novel Genomic Deletion c.505_513del ofDPYD

(2010) A. B. P. van Kuilenburg et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3)

(2009) André B. P. van Kuilenburg et al.   HUMAN GENETICS

UMD-predictor, a new prediction tool for nucleotide substitution pathogenicity-application to four genes:FBN1,FBN2,TGFBR1, andTGFBR2

(2009) Mélissa Yana Frédéric et al.   HUMAN MUTATION

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment

(2009) Ursula Amstutz et al.   PHARMACOGENOMICS

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients

(2008) Eva Gross et al.   PLoS One